These findings supported our hypothesis that PARD3 overexpression at the tumour initiation stage of hepatic diseases, which is probably due to a genetic instability-induced amplification mutation, contributes to tumorigenesis and progression in HCC. Here, PARD3 is linked to liver disorder.